Welcome to Drug and Alcohol Treatment
| ||
Drug Treatment Mdd Article
This is a selection made from among articles on Drug Treatment Mdd. For a permanent link to this article, or to bookmark it for future reading, click here.
What Everyone Ought To Know About Drug Treatment Centers
from: In the modern day, it seems as though substance abuse and alcoholism are two of the top issues that need to be dealt with. Once an alcoholic has identified him or herself as such, then it’s time that they reach out for help for their addiction. In many cases, the alcoholic’s family or friends have to take the first step in getting their loved one into a recovery state. Sometimes an intervention is staged, where the addict is given an ultimatum: go to rehab or get out of our lives. Other times, simply speaking concern to an addict can snap them back to reality and make them realize that their addiction has progressed into a disease and is affecting others.
After an addict is ready to seek help for his or her addiction, he or she is faced with the task of choosing drug treatment center to help them to stop abusing drugs. There are many different factors that, when combined, can help to make drug treatment either successful or unsuccessful.
The earlier that the addict recognizes that he or she has a problem, the better. The chance of a successful drug treatment is much better if the addict enters treatment as soon as possible. Above all, the addict’s commitment to the program is the main factor of him or her getting better. An addict needs to be motivated to quit their addiction and stay clean if any sort of drug treatment is going to work.
Every person is different; therefore, each person needs a different, individualized treatment program. The best drug treatment centers will base an individual’s program upon that individual’s specific needs and issues. The most effective treatments will offer many different approaches to drug treatment. While medical treatments do not cure substance abuse problems, they can be effective if used in addition to other treatments.
For a drug treatment to be successful, it’s important that the programs are carefully managed, step by step, by a professional. Most addicts relapse at least once after they complete treatment. Follow ups following completed drug treatment can help to prevent relapses from occurring.
Whether you yourself are an addict, or a loved one is an addict, you will most likely need help figuring out what drug treatment program is right for you. Stepping Stone Centers provides you with the most helpful resources to help you to find a drug treatment program ideal for you or your loved one’s situation.
About Author
SteppingStoneCenter.com is an admired resource for those affected with an addiction to find a drug treatment center that is right for them
Source: ArticleTrader.com
Drug Treatment Mdd Specific links
Drug Treatment Mdd News
Non-Drug Depression Treatment Rapidly and Significantly Improves Disease ... - MarketWatch (press release)
Non-Drug Depression Treatment Rapidly and Significantly Improves Disease ... MarketWatch (press release) NeuroStar TMS Therapy is the first and only TMS therapy for major depressive disorder cleared by the US Food and Drug Administration (FDA) that has been proven to achieve remission without systemic side effects in patients who have not found relief ... |
Non-Drug Depression Treatment Rapidly and Significantly Improves Disease ... - PR Newswire (press release)
Non-Drug Depression Treatment Rapidly and Significantly Improves Disease ... PR Newswire (press release) NeuroStar TMS Therapy is the first and only TMS therapy for major depressive disorder cleared by the US Food and Drug Administration (FDA) that has been proven to achieve remission without systemic side effects in patients who have not found relief ... |
TMS Improves Quality of Life in Drug-Resistant Depression - Medscape
TMS Improves Quality of Life in Drug-Resistant Depression Medscape ... impact on QoL during acute treatment. The NeuroStar (Neuronetics, Malvern, Pennsylvania) system used in the study was cleared for use by the US Food and Drug Administration (FDA) in 2008 for antidepressant-resistant major depressive disorder (MDD), ... |
Pfizer Announces New Long-Term Relapse Prevention Data For PRISTIQ(R ... - MarketWatch (press release)
Pfizer Announces New Long-Term Relapse Prevention Data For PRISTIQ(R ... MarketWatch (press release) (2,3,4) Pfizer has continued to research and evaluate PRISTIQ, a selective serotonin and norepinephrine reuptake inhibitor (SNRI), since it was approved by the US Food and Drug Administration (FDA) in 2008 for the treatment of MDD in adults. |
TMS Therapy Approved By FDA, Can Help People with Depression - Opposing Views
 Opposing Views | TMS Therapy Approved By FDA, Can Help People with Depression Opposing Views Patients with unipolar, non-psychotic Major Depressive Disorder (MDD) receiving transcranial magnetic stimulation (TMS) with NeuroStar TMS Therapy® achieved significant improvement with their depressive symptoms and in their quality of life. |
Neuralstem CEO to Present at the World Stem Cells and Regenerative Medicine ... - MarketWatch (press release)
Neuralstem CEO to Present at the World Stem Cells and Regenerative Medicine ... MarketWatch (press release) Mr. Garr's presentation, "Stem Cell Applications for Neurodegenerative Disorders," will review Neuralstem's cellular therapy trial in ALS, its neurogenic small molecule trial in major depressive disorder (MDD), and provide an overview on plans to ... |
Neuralstem Updates ALS Stem Cell Trial Progress - MarketWatch (press release)
Neuralstem Updates ALS Stem Cell Trial Progress MarketWatch (press release) ROCKVILLE, Md., May 8, 2012 /PRNewswire via COMTEX/ -- Neuralstem, Inc. (ASE:CUR) announced that the Federal Drug Administration (FDA) has approved the return of three patients from earlier cohorts in its ongoing Phase I safety trial to treat ... |
Neuralstem Reports First Quarter Financial Results And Provides Business And ... - MarketWatch (press release)
Neuralstem Reports First Quarter Financial Results And Provides Business And ... MarketWatch (press release) Dr. Johe continued, "This year will also see the start and finish of our neuroregenerative small molecule NSI-189 Phase Ib trial to treat major depressive disorder. This is a novel orally active drug that stimulates new neuron growth in the hippocampus ... Neuralstem Updates ALS Stem Cell Trial Progress |
Panel suggests DSM-5 psychiatry manual drops two disorders, keeps new autism ... - CBS News
 CBS News | Panel suggests DSM-5 psychiatry manual drops two disorders, keeps new autism ... CBS News Proponents of the diagnosis believe this addition could help people get treatment and prevent a serious condition, according to Nature. But the fear of the over-prescription of anti-psychotic drugs as opposed to using other treatments -- like therapy ... |
Vanda Pharmaceuticals Reports First Quarter 2012 Results - MarketWatch (press release)
Vanda Pharmaceuticals Reports First Quarter 2012 Results MarketWatch (press release) The tasimelteon MAGELLAN Phase IIb/III efficacy study for Major Depressive Disorder (MDD) is ongoing and Vanda expects to report top-line results in the first half of 2013. On April 16, 2012, Vanda announced that it had obtained exclusive world-wide ... |